![](https://www.microbiometimes.com/wp-content/uploads/2020/10/shutterstock_1005619948-326x245.jpg)
4D pharma plc announces merger with Longevity, a special purpose acquisition company (SPAC), and its intention to gain a NASDAQ listing
4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) – a novel class of drug derived from the microbiome – and Longevity Acquisition Corporation (NASDAQ: LOAC) (“Longevity”), a […]